Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199994 | 0.84 | TRPV1 (0.42) | PDE10APIK3CAMTOROPRK1TRPV1 | |
| SCHEMBL30336490 | 0.84 | TRPV1 (0.42) | PDE10APIK3CAMTOROPRK1TRPV1 | |
| SCHEMBL16467029 | 0.83 | PIK3CA (0.51) | PDE10APIK3CAMTOROPRK1TRPV1 | |
| SCHEMBL23623176 | 0.82 | OPRK1 (0.43) | PIK3CAMTOROPRK1TRPV1 | |
| SCHEMBL23625673 | 0.81 | KMT2A (0.44) | OPRK1TRPV1 | |
| SCHEMBL23623617 | 0.77 | PIK3CA (0.46) | PDE10APIK3CAMTOROPRK1TRPV1 | |
| SCHEMBL14784205 | 0.77 | ALDH1A1 (0.43) | OPRK1TRPV1 | |
| SCHEMBL14782147 | 0.77 | ALDH1A1 (0.47) | OPRK1TRPV1 | |
| SCHEMBL3549179 | 0.75 | FFAR4 (0.43) | PIK3CAMTOROPRK1 | |
| SCHEMBL3538620 | 0.75 | NEK2 (0.52) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837627-B1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2837627-A1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | IL5, IL2, IL4 | PDE10A 1504/4885PIK3CA 3797/4885MTOR 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.